Shell Asset Management Co. Acquires 19,014 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Shell Asset Management Co. increased its stake in Edwards Lifesciences Corporation by 45.1%, acquiring an additional 19,014 shares to reach a total of 61,172 shares worth approximately $4.78 million.
• Edwards Lifesciences Corporation reported an earnings per share (EPS) of $0.67 for the last quarter, exceeding estimates by $0.05 and achieving a revenue of $1.53 billion, up 11.9% year-over-year.
• Analysts have a Moderate Buy average rating for Edwards Lifesciences, with a target price of $87.06, reflecting a range of ratings including three Strong Buy, twelve Buy, and eight Hold.

Shell Asset Management Co. raised its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 45.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 61,172 shares of the medical research company's stock after buying an additional 19,014 shares during the quarter. Shell Asset Management Co.'s holdings in Edwards Lifesciences were worth $4,784,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of EW. Quantbot Technologies LP bought a new position in Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the 1st quarter valued at about $27,000. Global X Japan Co. Ltd. increased its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares during the period. Tradewinds Capital Management LLC increased its holdings in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the period. Finally, Rossby Financial LCC bought a new position in Edwards Lifesciences in the 1st quarter valued at about $29,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Argus upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the company an "outperform" rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Wall Street Zen downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 29th. Finally, Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $87.06.

Edwards Lifesciences Stock Up 0.2%

NYSE:EW opened at $76.70 on Wednesday. The firm's 50 day simple moving average is $78.39 and its 200 day simple moving average is $76.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a one year low of $64.51 and a one year high of $83.00. The company has a market cap of $45.03 billion, a PE ratio of 11.04, a P/E/G ratio of 3.68 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.